The role of targeted therapy for gastrointestinal tumors

Eugenio Fiorentino, Antonio Russo, Giuseppe Bronte, Giovanni Sortino, Francesco Passiglia, Konstantinos Papadimitriou, Christian Rolfo, Ghada Marogy, Marc Peeters, Konstantinos Papadimitriou, Francesco Passiglia

Risultato della ricerca: Article

24 Citazioni (Scopus)

Abstract

Many targeted drugs have been studied to target the molecular pathways involved in the development of gastrointestinal cancers. Anti-VEGF, anti-EGFR agents, and recently also multi-kinase inhibitor regorafenib, have already been available for the treatment of metastatic colorectal cancer patients. To date, Her-2 positive, gastric cancer patients, are also treated with trastuzumab, while the multi-targeted inhibitor, sorafenib, represents the standard treatment for hepatocellular carcinoma patients. Finally, sunitinib and everolimus, have been approved for the treatment of the neuroendocrine gastroenteropancreatic tumors. Actually a great number of further drugs are under preclinical and clinical development. The aim of this review is to provide a comprehensive overview of the state of art, focusing on the new emerging strategies in the personalized treatment of gastrointestinal tumors.
Lingua originaleEnglish
pagine (da-a)875-885
Numero di pagine11
RivistaEXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
Volume8
Stato di pubblicazionePublished - 2014

Fingerprint

Neoplasms
Gastrointestinal Neoplasms
Therapeutics
Pharmaceutical Preparations
Vascular Endothelial Growth Factor A
Stomach Neoplasms
Hepatocellular Carcinoma
Colorectal Neoplasms
Phosphotransferases
Everolimus
sorafenib
sunitinib
Trastuzumab
Gastro-enteropancreatic neuroendocrine tumor
regorafenib

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Medicine(all)
  • Gastroenterology

Cita questo

The role of targeted therapy for gastrointestinal tumors. / Fiorentino, Eugenio; Russo, Antonio; Bronte, Giuseppe; Sortino, Giovanni; Passiglia, Francesco; Papadimitriou, Konstantinos; Rolfo, Christian; Marogy, Ghada; Peeters, Marc; Papadimitriou, Konstantinos; Passiglia, Francesco.

In: EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, Vol. 8, 2014, pag. 875-885.

Risultato della ricerca: Article

@article{df878584679a474db3b33f889d6a97fb,
title = "The role of targeted therapy for gastrointestinal tumors",
abstract = "Many targeted drugs have been studied to target the molecular pathways involved in the development of gastrointestinal cancers. Anti-VEGF, anti-EGFR agents, and recently also multi-kinase inhibitor regorafenib, have already been available for the treatment of metastatic colorectal cancer patients. To date, Her-2 positive, gastric cancer patients, are also treated with trastuzumab, while the multi-targeted inhibitor, sorafenib, represents the standard treatment for hepatocellular carcinoma patients. Finally, sunitinib and everolimus, have been approved for the treatment of the neuroendocrine gastroenteropancreatic tumors. Actually a great number of further drugs are under preclinical and clinical development. The aim of this review is to provide a comprehensive overview of the state of art, focusing on the new emerging strategies in the personalized treatment of gastrointestinal tumors.",
author = "Eugenio Fiorentino and Antonio Russo and Giuseppe Bronte and Giovanni Sortino and Francesco Passiglia and Konstantinos Papadimitriou and Christian Rolfo and Ghada Marogy and Marc Peeters and Konstantinos Papadimitriou and Francesco Passiglia",
year = "2014",
language = "English",
volume = "8",
pages = "875--885",
journal = "Expert Review of Gastroenterology and Hepatology",
issn = "1747-4124",
publisher = "Taylor and Francis Ltd.",

}

TY - JOUR

T1 - The role of targeted therapy for gastrointestinal tumors

AU - Fiorentino, Eugenio

AU - Russo, Antonio

AU - Bronte, Giuseppe

AU - Sortino, Giovanni

AU - Passiglia, Francesco

AU - Papadimitriou, Konstantinos

AU - Rolfo, Christian

AU - Marogy, Ghada

AU - Peeters, Marc

AU - Papadimitriou, Konstantinos

AU - Passiglia, Francesco

PY - 2014

Y1 - 2014

N2 - Many targeted drugs have been studied to target the molecular pathways involved in the development of gastrointestinal cancers. Anti-VEGF, anti-EGFR agents, and recently also multi-kinase inhibitor regorafenib, have already been available for the treatment of metastatic colorectal cancer patients. To date, Her-2 positive, gastric cancer patients, are also treated with trastuzumab, while the multi-targeted inhibitor, sorafenib, represents the standard treatment for hepatocellular carcinoma patients. Finally, sunitinib and everolimus, have been approved for the treatment of the neuroendocrine gastroenteropancreatic tumors. Actually a great number of further drugs are under preclinical and clinical development. The aim of this review is to provide a comprehensive overview of the state of art, focusing on the new emerging strategies in the personalized treatment of gastrointestinal tumors.

AB - Many targeted drugs have been studied to target the molecular pathways involved in the development of gastrointestinal cancers. Anti-VEGF, anti-EGFR agents, and recently also multi-kinase inhibitor regorafenib, have already been available for the treatment of metastatic colorectal cancer patients. To date, Her-2 positive, gastric cancer patients, are also treated with trastuzumab, while the multi-targeted inhibitor, sorafenib, represents the standard treatment for hepatocellular carcinoma patients. Finally, sunitinib and everolimus, have been approved for the treatment of the neuroendocrine gastroenteropancreatic tumors. Actually a great number of further drugs are under preclinical and clinical development. The aim of this review is to provide a comprehensive overview of the state of art, focusing on the new emerging strategies in the personalized treatment of gastrointestinal tumors.

UR - http://hdl.handle.net/10447/109880

UR - http://www.future-drugs.com/page/journal/egh/teaser.jsp

M3 - Article

VL - 8

SP - 875

EP - 885

JO - Expert Review of Gastroenterology and Hepatology

JF - Expert Review of Gastroenterology and Hepatology

SN - 1747-4124

ER -